|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03759 PHARMARON
Nominal 
29.440 -0.740 (-2.452%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 7,595,424 | 17.924% | 14,095,079 | 12,275,775 | 11,537,996 | 10,266,288 |
| Cost of Sales | (5,120,555) | 19.954% | (9,237,745) | (8,126,520) | (7,443,176) | (6,517,012) |
| Gross Profit | 2,474,869 | 13.934% | 4,857,334 | 4,149,255 | 4,094,820 | 3,749,276 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (16,970) | -54.312% | (80,279) | (116,486) | (35,825) | (21,157) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 20,324 | -- | (135,612) | (123,256) | (2,084) | (33,851) | |
| Profit / (Loss) before Taxation | 926,178 | 13.955% | 1,912,710 | 2,091,263 | 1,837,887 | 1,666,391 | |
| Taxation | (214,475) | 33.941% | (357,524) | (377,104) | (256,106) | (314,254) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 38,491 | -21.070% | 108,713 | 79,192 | 19,315 | 22,467 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 750,194 | 6.957% | 1,663,899 | 1,793,351 | 1,601,096 | 1,374,604 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 76,957 | 0.323% | 153,414 | 170,087 | 148,649 | 132,099 |
| Depreciation & Amortisation | 722,396 | 18.537% | 1,269,620 | 1,145,412 | 1,008,588 | 766,063 |
| Directors' Emoluments | -- | -- | -- | 6,903 | 6,916 | 6,955 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 41.380 | 3.865% | 94.430 | 101.330 | 90.330 | 77.500 |
| DPS (cts) | 0.000 | -- | 20.000 | 20.000 | 20.000 | 20.000 |
| Dividend Payout Ratio (%) | -- | -- | 21.180% | 19.737% | 22.141% | 25.806% |
| Cash flow per share ($) | -- | -- | 1.828 | 1.456 | 1.554 | 1.209 |
| NBV per share ($) | 8.934 | -- | 8.506 | 7.690 | 6.917 | 5.793 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 750,194 |
| %Change | 6.957% |
| EPS / (LPS) | RMB 0.414 |
| NBV Per Share (¥) | RMB 8.934 |